My watch list  

OSI Pharmaceuticals

OSI Pharmaceuticals, Inc.
Founded? (?)
HeadquartersMelville, New York
Key peopleColin Goddard, CEO & Direcdtor
Michael G. Atieh, CFO
IndustryHealth Care
ProductsMedical Laboratories & Research
Revenue$417.14 MillionUSD (2006)
Net income$-534.00 Million USD (2006)
Employees611 (2007)
SloganShaping Medicine, Changing Lives

OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ Biotechnology Index.

OSI's oncology products include Tarceva (Erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR), which was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. The company's research and development capability includes high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms.

Research and development on therapies for metabolic diseases, particularly type 2 diabetes and obesity, is conducted through their U.K. subsidiary Prosidion Limited.

OSI has approximately 500 staff in research and development, regulatory, sales, marketing, commercial and business.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "OSI_Pharmaceuticals". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE